Odonate Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Kevin Tang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 11.9yrs |
| CEO ownership | n/a |
| Management average tenure | 7.2yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Nov 18
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Jun 09Odonate Therapeutics: Lessons Learned
Apr 27We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate
Mar 09Revisiting Odonate Therapeutics
Feb 01Odonate: A Simple Story Of An Oral Taxane
Jan 10Odonate Therapeutics: Likely Tesetaxel Approval Means Company Is Undervalued
Jan 08Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares
Jan 07Odonate CEO buys $4.2M shares
Dec 24Odonate announces positive Phase 3 data in metastatic breast cancer
Dec 11Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?
Dec 09
Odonate Therapeutics EPS in-line
Oct 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$119m |
| Mar 31 2021 | n/a | n/a | -US$130m |
| Dec 31 2020 | US$1 | US$1 | -US$126m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$118m |
| Mar 31 2020 | n/a | n/a | -US$113m |
| Dec 31 2019 | US$1 | US$1 | -US$112m |
| Sep 30 2019 | n/a | n/a | -US$113m |
| Jun 30 2019 | n/a | n/a | -US$110m |
| Mar 31 2019 | n/a | n/a | -US$101m |
| Dec 31 2018 | US$1 | US$1 | -US$89m |
| Sep 30 2018 | n/a | n/a | -US$76m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$1 | US$1 | -US$33m |
Compensation vs Market: Insufficient data to establish whether Kevin's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Kevin's compensation with company performance.
CEO
Kevin Tang (57 yo)
11.9yrs
Tenure
US$1
Compensation
Mr. Kevin C. Tang is Director of Aurinia Pharmaceuticals Inc. from September 2024 & serves as its Chairman. Mr. Tang serves as Director at Tetraphase Pharmaceuticals, Inc. since July 28, 2020. He has been...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 11.9yrs | US$1.00 | no data | |
| CFO & Principal Accounting Officer | 6.1yrs | US$572.17k | no data | |
| Senior Vice President of Operations | no data | no data | no data | |
| Senior Vice President of Technical Operations | 8.3yrs | no data | no data | |
| Chief Scientific Officer | 6.1yrs | no data | no data |
7.2yrs
Average Tenure
52.5yo
Average Age
Experienced Management: ODTC's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 11.9yrs | US$1.00 | no data | |
| Independent Director | 6yrs | US$249.44k | no data | |
| Independent Director | 8yrs | no data | no data | |
| Independent Director | 7.4yrs | US$274.44k | no data | |
| Director | 7.4yrs | US$249.44k | no data |
7.4yrs
Average Tenure
59yo
Average Age
Experienced Board: ODTC's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 11:03 |
| End of Day Share Price | 2024/12/05 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Odonate, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dana Flanders | Goldman Sachs |
| Michael Yee | Jefferies LLC |
| Eric Schmidt | TD Cowen |